Advertisement

Topics

Paradigm Therapeutics Ltd Company Profile

13:28 EST 16th December 2018 | BioPortfolio

Paradigm Therapeutics was founded in 1999 and has established world class target identification and validation capabilities based on gene knock out technology and in vivo pharmacology. The acquisition of Amedis Pharmaceuticals in January 2005 added key medicinal chemistry skills. The combined company has focused on the identification of novel, small molecule tractable targets with defined therapeutic utility within key gene families such as G-protein coupled receptors (GPCRs), ion channels and proteases. The company has developed a drug discovery pipeline comprising targets and late stage pre-clinical projects in key areas of unmet medical need in pain, CNS disorders, hormone dependent diseases such as prostate and breast cancer and metabolic diseases such as diabetes, hyperlipidemias, obesity and osteoporosis. In June 2005 Paradigm Therapeutics announced two major collaborations with Ortho-McNeil Pharmaceuticals (J&J) in pain and urinary urge incontinence and with Takeda in CNS disorders. The company is based in Cambridge UK and Singapore.

Location

418 Cambridge Science Park
CAMBRIDGE
Cambridgeshire
CB4 0PA
United Kingdom

Contact

Phone: 44 (0)1223 477910
Fax: 44 (0)1223 477911
Email: info@paradigm-therapeutics.com


News Articles [849 Associated News Articles listed on BioPortfolio]

CLL Paradigm Continues to Be Refined

Erlene Seymour, MD, discusses novel therapies as well as their potential applications in the treatment paradigm of chronic lymphocytic leukemia.

RTI Surgical to buy Paradigm Spine in $300m deal

Founded in 2005, Paradigm Spine is a privately held company engaged in the design and development of solutions for the disease management of spinal stenosis. The company’s coflex The post RTI S...

Prostate Cancer Paradigm Progresses, But Unanswered Questions Remain

Randy F. Sweis discusses recent progress and next steps in the prostate cancer paradigm.

RTI Surgical CEO discusses growth plans after Paradigm buy

RTI Surgical, which is set to buy Paradigm Spine, plans to support that move with "more innovation" to "fuel organic and inor -More- 

Expert Identifies Biggest Shifts in Ovarian Cancer Paradigm

Jonathan S. Berek, MD, MMS, outlines the changing paradigm of ovarian cancer.

RTI Surgical enters into definitive agreement to acquire Paradigm Spine

RTI Surgical, Inc., a global surgical implant company, and Paradigm Spine, LLC, a leader in motion preservation and non-fusion spinal implant technology, today announced that they have entered into a ...

The biggest paradigm shift in decades? ICH E6 R2

ICH E6 R2 sparked a paradigm shift, though 2019 will see the clinical trials industry transition from a risk-based monitoring approach to risk-based quality management.

Paradigm Spine scores reimbursement win for stabilization implant

Paradigm Spine has obtained coverage from Blue Cross Blue Shield of South Carolina for its coflex interlaminar stabilization  -More- 

PubMed Articles [684 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Pilot for novel context generalization paradigm.

Following an aversive experience, fears often generalize across contexts. Contextual fear generalization is modeled in a laboratory paradigm in which one context (CTX+) is paired with an aversive unco...

Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers.

The effective delivery of target-specific siRNA to the brain by exploiting the exosomes derived from dendritic cells renders the paradigm shift for the prospective use of nanosized exosomes as a deliv...

From Child Protection to Paradigm Protection-The Genesis, Development, and Defense of a Scientific Paradigm.

A scientific paradigm typically embraces research norms and values, such as truth-seeking, critical thinking, disinterestedness, and good scientific practice. These values should prevent a paradigm fr...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

Clinical Trials [408 Associated Clinical Trials listed on BioPortfolio]

Feasibility Study of Effective Methods for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness

Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections. Evaluate the educationa...

Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes

The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control whe...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Feasibility Trial of rTMS for Cannabis Use Disorder

This small pilot trial will recruit 10 cannabis use disordered participants and apply 20 sessions of rTMS in conjunction with a two session Brief Marijuana Dependance Counseling treatment ...

Companies [1352 Associated Companies listed on BioPortfolio]

Paradigm Therapeutics Incorporated

Paradigm Therapeutics is an emerging drug discovery company focussed on the pharmaceutical exploitation of the human genome. The race to define biological function of the thousands of uncharacterised ...

The Paradigm Award Committee

The Paradigm Award was created to honor hospitals that have gone above and beyond in their efforts to foster efficient labor practices without resorting to workforce reductions or dramatic top-down ma...

Paradigm Medical Industries

Founded in 1996, Paradigm Medical Industries, Inc. develops, manufactures, and markets diagnostic and surgical equipment for the ophthalmic market. The company specialized in powerful, easy-to-use, v...

Semma Therapeutics, Inc.

Semma Therapeutics is pioneering the new treatment paradigm of using cells as medicine. Semma’s new class of regenerative medicine therapies couples its breakthrough stem cel...

Nimbus Therapeutics, LLC

Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pi...

More Information about "Paradigm Therapeutics Ltd" on BioPortfolio

We have published hundreds of Paradigm Therapeutics Ltd news stories on BioPortfolio along with dozens of Paradigm Therapeutics Ltd Clinical Trials and PubMed Articles about Paradigm Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Paradigm Therapeutics Ltd Companies in our database. You can also find out about relevant Paradigm Therapeutics Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record